Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$6.56 USD
+0.13 (2.02%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.58 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MESO 6.56 +0.13(2.02%)
Will MESO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MESO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MESO
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
MESO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
5 Stocks to Ride the Santa Claus Rally
Other News for MESO
Mesoblast Anticipates FDA Decisions, Manages Finances
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Mesoblast upgraded to Overweight at Piper after FDA accepts Ryoncil BLA
Piper Sandler gets more bullish on Mesoblast, upgrades shares